Melanoma D008545

Description

A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)   MeSH

Hierarchy View

Subtype Terms (3)

Melanoma, Experimental
5 drugs (3 approved, 2 experimental)


Phase 3 Indicated Drugs (84)

Phase 2 Indicated Drugs (490)

12 peptide melanoma vaccine

131i-tm-601

18f-fluciclatide

3,4-dihydroxyphenylalaninechrome tautomerase

4-1bb selected til

4b5

4-peptide melanoma vaccine

4sc-202

68ganota-anti-mmr-vhh2

6mhp

7-hydroxystaurosporine

ab154

ab928

abemaciclib (verzenio)

abt-510

acetylcysteine (mucomyst)

acetylsalicylic acid (aspirin)

acitretin (soriatane)

adenoviral vector expressing hsv-tk

afatinib (gilotrif)

aflibercept (zaltrap)

agatolimod

alectinib (alecensa)

alks 4230

allogeneic large multivalent immunogen vaccine

allogeneic lymphocytes

allogeneic natural killer cells

alocelyvir

alpha-type-1-polarized dendritic cell

alt-801

alt-803

alvac gp100 vaccine

alvac mart-1 vaccine

alvac melanoma multi-antigen therapeutic vaccine

alvac ny eso-1 vaccine

alvocidib

aminolevulinic acid (levulan)

anlotinib

anti-gp100:154-162 tcell receptor peripheral blood lymphocyte

anti-gp 100:154 tcell receptor peripheral blood lymphocyte

anti-mart-1 f5 tcr pbl

antineoplaston a10

anti-ny eso-1 mtcr pbl

anti-ny eso-1 t cell receptor cd62l+ cells

anti-ny eso-1 t-cell receptor pbl

anti-ox40

anti-p53 t-cell receptor-transduced peripheral blood lymphocytes

anti-tac(fv)-pe38

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin)

anti-vegfr2 car cd8 t cells

apatinib

apg-115

apo-866

apx005m

arag

arsenic trioxide (trisenox)

as15

ast-008

au-011

autologous anti-gp 100:154-162 t-cell receptor gene-engineered peripheral blood lymphocytes

autologous anti-gp 100:154-162 t-cell receptor gene-engineered tumor infiltrating lymphocytes

autologous anti-mart-1 f5 t-cell receptor

autologous anti-mart-1 f5 t-cell receptor gene-engineered peripheral blood lymphocytes

autologous anti-mart-1 f5 t-cell receptor gene-engineered tumor infiltrating lymphocytes

autologous dendritic cells

autologous dendritic cells electroporated with wt1 mrna

autologous dendritic cells loaded with autologous tumor lysate

autologous dendritic cells loaded with mage-a3, melana and survivin

autologous dexosomes loaded with tumor-specific peptides

autologous lymphocytes

autologous melanoma lysate/klh-pulsed autologous dendritic cell vaccine

autologous trimix-dc

autologous tumor cell vaccine

autologous tumor infiltrating lymphocytes

avapritinib (Ayvakit)

avelumab (bavencio)

azacitidine (vidaza)

azd-4547

azd-5672

azd6738

bacitracin (polysporin)

bardoxolone

bcd-100

bcd-217

betamethasone (celestone)

bevacizumab (avastin)

bgb-10188

bi-2536

bifidobacterium animalis

bintrafusp alfa

bnt111

bo-112

boronophenylalanine-fructose complex

bortezomib (velcade)

bosentan (tracleer)

brentuximab vedotin (adcetris)

budesonide (rhinocort)

buparlisib

bvd-523

bystander-based autologous tumor cell vaccine

cabozantinib (cometriq)

cadi-05

calcitriol (rocaltrol)

camrelizumab

canakinumab (ilaris)

candida albicans allergen

cap-232

capmatinib

cb-10-01

cc-122

cd24fc

cd25-depleted peripheral blood mononuclear cell

cd40 ligand

cd8 enriched young til

cd8+ t cells

cdx-301

cediranib

celecoxib (celebrex)

cemiplimab (libtayo)

ceralasertib

ceritinib (zykadia)

chir-265

cilengitide

cimetidine (tagamet)

cixutumumab

cm082

coxsackievirus a21

crizotinib (xalkori)

cx-072

cy-503

cyclosporine (sandimmune)

cyt004-melqbg10

cytokine induced killer cells

cytolytic t-lymphocytes

d1/3-mage-3-his fusion protein

dactinomycin (cosmegen)

dasatinib (sprycel)

dcb-bo1301

dc vaccine

dec-205/ny-eso-1 fusion protein cdx-1401

decitabine (dacogen)

defactinib

dendritic cell-gp100-mart-1 antigen vaccine

dendritic cell-idiotype-keyhole limpet hemocyanin vaccine

dendritic cell-mart-1 peptide vaccine

dendritic cells - transfected with htert-, survivin- and tumor cell derived mrna + ex vivo t cell expansion and reinfusion

dendritic cell tumor fusion vaccine

denenicokin

denileukin diftitox (ontak)

denosumab (prolia)

detoxpc

dexamethasone

diclofenac (voltaren)

dinaciclib

dinitrophenyl

disulfiram (antabuse)

docetaxel (taxotere)

dostarlimab

drosophila-peptide pulsed melanoma-reactive autologous cd8+ pbl

durvalumab (imfinzi)

duvelisib (copiktra)

e7016

e 7070

e7449

elacytarabine

emd 273063

emd 521873

enalapril (vasotec)

endostatin (endostar)

ensartinib

entinostat

entrectinib (Rozlytrek)

epirubicin (ellence)

epothilone

erlotinib (tarceva)

etaracizumab (abegrin)

ethiodol

everolimus (zortress)

evofosfamide

evx-02

f16il2

f5 tcr transgenic cells

famitinib

fludeoxyglucose f-18

fludrocortisone (florinef)

fluoromisonidazole

fluorothymidine

flx475

fowlpox virus vaccine

gadolinium

ganetespib

ganitumab

gefitinib (iressa)

gemcitabine (gemzar)

gen-009

gen0101

glembatumumab vedotin

glycoprotein 100

gm-ct-01

gntv

golnerminogene pradenovec

gp100:154-162

gp100: 209-217

gp100:280-288

gp209-2m antigen

green tea

gr-md-02

gsk1203486a

gsk-2636771

guadecitabine

hf10

hla-a1-binding mage-1/mage-3 multipeptide-pulsed autologous dendritic cell vaccine

hla-a2-binding tyr/mart-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine

hlx208

hp802-247

human fecal microbiota

human papillomavirus 16 monovalent

hx008

hyaluronidase (human recombinant) (hylenex)

hydroxychloroquine (plaquenil)

hyperacute

hyperacute-melanoma vaccine

iab22m2c

ibrutinib (imbruvica)

ibuprofen (motrin)

icosmatrix

ide196

il-12 transduced til

il15-dc vaccine

imatinib (gleevec)

imm-101

immune globulin (human)

imprime pgg

imtox-25

imvamune

incb086550

incmga00012

incomplete freund's adjuvant

indomethacin (indocin)

infigratinib

infliximab (remicade)

ingn 241

interferon alpha-1

interleukin-12

interleukin-15

interleukin-2 gene

interleukin-4

in vitro-treated peripheral blood stem cell

irradiated donor lymphocyte

isosulfan blue (lymphazurin)

isotretinoin (accutane)

ispinesib

itil-168

ixabepilone (ixempra)

karenitecin

kw2871

ladiratuzumab vedotin

lag525

lapatinib (tykerb)

larotrectinib (vitrakvi)

leuprolide (lupron)

lifileucel

liposomal interleukin-2

ln-145

lomustine

lovastatin (mevacor)

lpv7

ltt462

lxh254

ly900003

lymphocytes

lymphokine-activated killer cells

maat013

mage-3

mage-3.1 antigen

mage-3.a1

mage-3.a1 peptide

mage-3/melan-a/gp100/na17 pbmc, rhil-12

mage-3/melan-a/gp100/na pbmc

mage-a3 asci

mage-a3 peptide

mart-1

mart-1, gp100, tyrosinase peptides

mart-1 peptide pulsed dendritic cells

mart-1 reactive cd8+ pbl

mc2 tcr T cells

melanoma antigens-specific cd8+ t lymphocytes

melanoma peptide-pulsed dendritic cells

melanoma reactive til

melanoma vaccine

melatonin

melitac 12.1 peptide vaccine

mesna (mesnex)

metformin (glucophage)

methylprednisolone (medrol)

mgi-114

mk-1775

mkc1106

montanide isa 720

morab-004

mpc-6827

mpla

mrna-4157

msk-2206

multi-epitope melanoma peptide vaccine

muromonab cd3 (Orthoclone OKT3)

mycophenolate (myfortic)

n-(4-hydroxyphenyl)all-trans retinamide

na17.a2

na17.a2 peptide

naltrexone (revia)

navitoclax

naxitamab

nbtxr3

nelfinavir (viracept)

neoantigen-based melanoma vaccine

nicotinamide

nilotinib (tasigna)

nintedanib (ofev)

nir178

niraparib (zejula)

ny-eso-1

ny-eso-1 and melan-a/mart-1 peptides

ny-eso-1 iscomatrix

ny-eso-1 reactive tcr retroviral vector transduced autologous pbl

o6-benzylguanine

obatoclax

obp-301

octreotide (sandostatin)

ofatumumab (arzerra)

olaparib (lynparza)

omaveloxolone

onc-392

oncoxin-viusid

orienx010

osi-461

osimertinib (tagrisso)

oxaliplatin (eloxatin)

ozurdex

pac-1

palbociclib (ibrance)

panobinostat (farydak)

pazopanib (votrient)

pbmcs

pd-l1/ido peptide vaccine

peginterferon beta-1a (Plegridy)

pegylated arginine deiminase

pemetrexed (alimta)

pentamidine (pentam)

perifosine

peripheral blood hematopoietic cell

pertuzumab (perjeta)

pexa-vec

pexidartinib (Turallo)

pf-04878691

pg13-mage-a3 tcr9w11 transduced autologous peripheral blood lymphocytes

pg545

phenylacetic acid (ucephan)

phenylacetylgluatmine

pi-88

pidilizumab

pimasertib

pimonidazole

plinabulin

plx2853

polidocanol (asclera)

polyethylene glycol

poly-iclc

potassium alum

prednisolone (hydeltra)

prednisone (meticorten)

prostvac-v/tricom

psilocybin

pvsripo

pyrazoloacridine

qs-21

ramucirumab (cyramza)

rapa-201 autologous t cells

ras peptide cancer vaccine

rc48-adc

recmage-a3

recombinant adenoviral human p53 gene

recombinant fowlpox-tyrosinase vaccine

regorafenib (stivarga)

reolysin

replication-competent hsv-1 oncolytic virus

resimmune

resiquimod

retinoic acid

retinoid 9cuab30

rf-go 100p209

ribociclib (kisqali)

riluzole (rilutek)

rintatolimod

rituximab (rituxan)

riviciclib

ro4929097

ro7198457

romidepsin (istodax)

romiplostim (nplate)

rosiglitazone

rp1

rubitecan

rucaparib (rubraca)

sagopilone

sapanisertib

saracatinib

sb-485232

sb-as15

sb-as2

sd-101

sea-cd40

selinexor (Xpovio)

sentoclone

sepantronium bromide

shr-1701

sitagliptin (januvia)

sitravatinib

sotrastaurin

sterculia

sulindac (clinoril)

sunitinib (sutent)

talabostat

talazoparib (talzenna)

tamoxifen (nolvadex)

tanespimycin

taselisib

tasidotin

tavokinogene telseplasmid

taxoprexin

tazemetostat

tbio-6517

tcr transduced t-cells

tebentafusp

telomerase: 540-548 peptide vaccine

temsirolimus (torisel)

tesetaxel

tetanus peptide melanoma vaccine

tetanus toxoid

tgfbdnrii-transduced autologous tumor infiltrating lymphocytes

thalidomide (Thalomid)

thymalfasin (zadaxin)

tilsotolimod

tiomolibdate ion

tiragolumab

tislelizumab

t lymphocytes

tocilizumab (actemra)

tpi-287

tq-b2450

tramadol (Ultram)

trastuzumab emtansine (kadcyla)

tretinoin (Retin-A)

trigriluzole

trophosphamide

troriluzole

tsr-022

tyrosinase

tyrosinase/gp100/mart-1 peptides

tyrosinase-related protein-1

uprosertib

urea

urelumab

uv1 vaccine

v937

vaccinia-gm-csf vaccine

vaccinia-tyrosinase vaccine

valaciclovir (Valtrex)

valproic acid (depakene)

varlilumab

vatalanib

vegfr1-a24-1084

veliparib

verteporfin (visudyne)

vigil

vincristine (oncovin)

vinorelbine (navelbine)

vismodegib (erivedge)

volociximab

vorinostat (zolinza)

vs-6766

VSV-IFNβ-NIS

wild-type reovirus

yh003

young tumor infiltrating lymphocytes

zanolimumab

zanubrutinib (Brukinsa)

zarnestra

zinc dichloride

zkab001

Phase 1 Indicated Drugs (373)

131i-mip-1145

188re-pti-6d2

18f-fmau

18f mel050

[203pb]vmt01

4-1bbζ b7h3-egfrt-dhfr

4-1bbζ cd19-her2tg

[68ga]-nota-hgzp

[68ga]vmt02

70-kd heat-shock protein

ab308

abexinostat

acy-241

adct-301

adenovirus rsv-tk

ad-magea3

adu-1604

advtmm2/dc vaccine

adxs-neo

akti-treated til

alemtuzumab (campath)

alisertib

allogeneic hematopoietic stem cells (Hemacord)

allogeneic k562 tumor cells

alpelisib (Piqray)

alprostadil (prostin)

alvac-hb7.1

alvespimycin

amd-070

amg 228

amifostine (ethyol)

anti-ny eso-1 tcr-transduced t cells

arg1-18,19,20

as1409

asn003

asn007

atrc-101

autologous bulk til 1383i tcr transduced t cells

autologous cytokines

autologous dendritic cell adenovirus ccl21 vaccine

autologous genetically modified mage a10c796 t cells

autologous genetically modified mage a4c1032 t cells

autologous genetically modified t cells, ny-eso-1c259 t

autologous hematopoietic cell

autologous, lethally irradiated melanoma cells

autologous natural killer cells

autologous til 1383i tcr gene modified t cells

av-mel-1

azd8701

b7-h3 car-t

bat4706

bavituximab

bay2666605

bcd-135

bcd-145

betulinic acid

bi 754091

bi 765063

bibw2

bivalent oral polio vaccine (bopv), type 1 and type 3

bleomycin (blenoxane)

bms-936559

bms-982470

bpx-701

bryostatin

bupropion (wellbutrin)

busulfan (myleran)

buthionine sulfoximine

cabiralizumab

caffeine

can04

canarypox-hil-12 melanoma vaccine

capecitabine (xeloda)

carboxyamidotriazole

cavatak

cbl0137

cc-486

cct3833

cd20 car-t cells

cd4+ t cells

cefazolin (ancef)

certolizumab pegol (cimzia)

cetuximab (erbitux)

cmb305

colloidal gold-bound tumor necrosis factor

cosibelimab

cp-870893

cpg

cv8102

cva21

dc/apo-nec

dcc-3116

dedn6526a

dextromethorphan (delsym)

digoxin (lanoxin)

dimethyl sulfoxide (rimso)

dinutuximab (unituxin)

diphenhydramine (benadryl)

diphenylcyclopropenone

dky709

dnx-2440

dropropizine

ds-8273a

dsp-7888

dt01

e-6201

eci-006

ef5

enoblituzumab

enzalutamide (xtandi)

eribulin (halaven)

etoposide (vepesid)

evax-01-caf09b

ex vivo-activated autologous lymph node lymphocytes

famotidine (pepcid)

fate-nk100

fcn-159

fentanyl (Innovar)

fexofenadine (allegra)

fhd-286

flanvotumab

flucytosine (ancobon)

fluma peptide

flu matrix peptide p58-66

fluorouracil (efudex)

gad-pev

gave melanoma

gc1008

gd0-994

gd2-sada

gen-011

geniusvac-mel4

gimeracil

gnr-051

gp100-fowlpox vaccine

gp75 dna vaccine

grn-1201

gsk2241658a

gsk2302025a

gsl alpha-gal

gvax pancreatic cancer vaccine

hgm-csf herpes simplex virus injection

hm95573

hsp110-gp100 chaperone complex vaccine

human gp100 plasmid dna vaccine

humax-il8

icon-1

icovir-5

idc-g305

id-lv305

ido peptide

ifx-hu2.0

igf-methotrexate

ikkb matured dendritic cells

il-12 & anti-ny eso1 tcr pbl

il13ralpha2-specific hinge-optimized 4-1bb-co-stimulatory car/truncated cd19-expressing autologous tn/mem cells (Biological)

il-7

in10018

inactivated influenza vaccine

inbrx-105

inbrx-106

incb050465

incyclinide

ino-1001

interferon alfa-1b

interleukin-10

inxn-3001

ipi-549

ipn60090

irinotecan (Camptosar)

itacitinib

itraconazole (sporanox)

ivac mutanome

js004

ketoconazole (nizoral)

keyhole limpet hemocyanin

kin-2787

klh

langerhans-type dendritic cells

lbl-007

lefitolimod

leflunomide (arava)

letrozole (femara)

leucovorin

levobupivacaine (chirocaine)

lgk974

lipo-merit

lipopolysaccharide


Organization Involved with Phase 3 Indications (117)

Organization Involved with Phase 2 Indications (380)

4SC AG

A2 Healthcare Taiwan Corporation

Abbott

AbbVie

Academic and Community Cancer Research United

Achilles Therapeutics Ltd

Actelion

Adaptimmune

AGIRx

AgonOx

Akeso Pharmaceuticals, Inc.

Alcedis GmbH

Allergan

Altor Bioscience

American Association for Cancer Research

American Society of Clinical Oncology

AmpliMed Corporation

AnewPharma

Angimmune LLC

Anosys

Apeiron Biologics

Apexigen, Inc.

Aprea Therapeutics AB

Aqualis

Ascentage Pharma Group Inc.

Assistance Publique - Hôpitaux de Paris

Astellas

Astex Pharmaceuticals, Inc.

Attenuon

Aura Biosciences

Australia and New Zealand Melanoma Trials Group

BerGenBio ASA

Billings Clinic

Biocad

Biogen

BioMed Valley Discoveries, Inc

Biontech

BioNumerik Pharmaceuticals, Inc.

Biothera

Boehringer Ingelheim

British Columbia Cancer Agency

Brown University

Burzynski Research Institute

Butantan Institute

Cadila Healthcare

California Cancer Assocaties for Research & Excellence

California Institute of Technology

California Pacific Medical Center Research Institute

Calithera Biosciences

Cancer Biotherapy Research Group

Cancer Immunotherapy Trials Network

Cancer Insight, LLC

Cancer Research Institute

Cancer Research UK

Cancer Treatment Centers of America

Cancer Trials Ireland

Cantonal Hospital of St. Gallen

Cardinal Health

Cascadian Therapeutics Inc.

Case Western Reserve University

Catalysis SL

Celldex Therapeutics

CellSight Technologies, Inc.

Center Eugene Marquis

Centocor

Centre Pluridisciplinaire d'Oncologie & LICR, CHUV

Chao Family Comprehensive Cancer Center

Checkmate Pharmaceuticals

Chinese University of Hong Kong

Chiron

City of Hope National Medical Center

ClinAssess GmbH

Clinical Research Technology S.r.l.

Clinigen, Inc.

Coborn Cancer Center

Columbia University

Comprehensive Cancer Centers of Nevada

Cornell University

Cortice Biosciences, Inc.

Cosmo Pharmaceuticals

Covance

CuraGen

Cytavis Biopharma GmbH

CytomX Therapeutics

Cytos Biotechnology AG

Daiichi Sankyo

Dartmouth University

Dragonfly Therapeutics

Duke University

Dutch Cancer Society

Dynavax Technologies Corporation

Elios Therapeutics, LLC

Ella Therapeutics Ltd

Eudax S.r.l.

European Association of Dermato Oncology (EADO)

Evaxion Biotech A/S

Evelo Biosciences

Exelixis

Expert Committee for Melanoma of CSCO

FeRx

Fondazione Melanoma Onlus

Free University of Amsterdam

Free University of Brussels

Fudan University

Fujian Medical University

GammaCan

Gemin X

General Electric

Genocea Biosciences, Inc.

GenVec

Georgetown University

German Research Foundation

Ghent University

Government of Russia

Gradalis, Inc.

Greenville Health System

Grupo Español Multidisciplinar de Melanoma

Gundersen Health System

Hackensack University Medical Center

HealthPartners Institute

Henan Medical University

Hengrui Therapeutics, Inc.

Hoag Memorial Hospital Presbyterian

Hoosier Cancer Research Network

Hospital General Universitario Gregorio Marañon

Hospital Rudolfstiftung

ICO Hospital Durans i Reynals

IDEAYA Biosciences

IFO Polo Oncologico Ist. Regina Elena, Roma

Ignyta, Inc.

Immodulon Therapeutics Ltd

Immunocore Ltd

Immunovative Therapies

Immutep S.A.

INC Research

Infinity Pharmaceuticals, Inc.

Inova Health System

Institut Català d'Oncologia

Instituto de Investigação em Imunologia

Institut Pasteur

Intergruppo Melanoma Italiano

Introgen Therapeutics

Iovance

IQVIA

Isala Clinics, Zwolle, The Netherlands

Ishihara Sangyo Kaisha, Ltd.

Istari Oncology, Inc.

Istituto Nazionale per lo Studio e la Cura dei Tumori

James Graham Brown Cancer Center

Jennerex Inc.

Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd

Jilin University

Jinan University

Johnson and Johnson

John Wayne Cancer Institute

J. W. Goethe University

Kantonsspital Graubünden

Kechow Pharma

Keio University

Key Biologics, LLC

K-Group Beta

Kiang Wu Hospital

Kyowa Hakko Kirin

Leadiant Biosciences, Inc.

Life Sciences Pharmaceuticals

Lokon Pharma AB

Loma Linda University

Loyola University

Ludwig Institute for Cancer Research

Lund University

MannKind Corp

Manuel Fajardo Clinical Surgical University Hospital

Maria Sklodowska Curie Children's Hospital

Mary Crowley Cancer Center

McGill University

Medigen Biotechnology Corporation

MedImmune

Medivation

Melanoma Research Alliance

Melanoma Research Foundation Breakthrough Consortium

Melanoma Research Institute

Memgen, LLC

Memorial Sloan-Kettering Cancer Center

Merck KGaA

Merck Serono

Mercy Health, Grand Rapids

Methodist Cancer Center, Houston, Texas

MFAR Clinical Research

Midwest Melanoma Partnership

Mirna Therapeutics

Moderna Therapeutics

Moorgreen Hospital, Southampton

Morphotek

Mt. Sinai Medical Center, Miami

Multidisciplinary Association for Psychedelic Studies

Myrexis Inc.

Nanjing University

Nanobiotix

NantCell, Inc.

National Cancer Institute, France

National Center for Research Resources (NCRR)

National Comprehensive Cancer Network

Nationales Centrum fur Tumorerkrankungen

National Heart, Lung, and Blood Institute (NHLBI)

National Institute for Health Research, United Kingdom

Nebraska Cancer Specialists

NeoPlas Innovation

Netherlands Working Group on Immunotherapy of Oncology

Newcastle University

New Mexico Cancer Care Alliance

New York University

North Central Cancer Treatment Group

Northern California Melanoma Center

Northern California Melanoma Center, St. Mary's Medical Center

Northwestern University

Norwegian Cancer Society

Notre-Dame Hospital, Paris

Novelion Therapeutics

NovoCure Ltd.

Novo Nordisk

Novotech

Ochsner Health System

ODC Therapy

OHARA Pharmaceutical Co., Ltd.

Oncolix, Inc.

Oncology Service, Wills Eye Institute

Oncolys BioPharma Inc

Oncolytics Biotech

OncoSec Medical Incorporated

Oncovir, Inc.

Onxeo

OrienGene Biotechnology Ltd.

OSI Pharmaceuticals

Palmetto Hematology Oncology, P.C.

PDL BioPharma

Peking University

Pennsylvania State University

Peter MacCallum Cancer Centre

Petrov Research Institute of Oncology

PharmaBio Development Inc.

Pierre Fabre

Piramal

Plexxikon

Point Therapeutics

Precision Medicine

Progen Pharmaceuticals

Provenance Biopharmaceuticals

Providence Health & Services

Reata Pharmaceuticals, Inc.

Regeneron

Replimune Inc.

Rhode Island Hospital

RIZIV

Rotterdam Eye Hospital

Royal Liverpool & Broadgreen University Hospitals NHS Truts

Royal Marsden Hospital NHS Trust

Russian Academy of Medical Sciences

Saint Francis Memorial Hospital

Saint John's Health Center - John Wayne Cancer Institute (JWCI)

San Diego Pacific Oncology & Hematology Associates

Sanofi

Scancell Ltd

SCRI Development Innovations

SentoClone AB

Seoul National University

ShangHai HaiHe Pharmaceutical

Shenzhen Hank Bioengineering Institute

Simcere Pharmaceutical Co., Ltd

Society of Surgical Oncology (SSO)

Spectrum Pharmaceuticals

Stand Up To Cancer

Stanford University

State of Texas

State University of New York, Buffalo

Stemcentrx

St. Jude Children's Hospital

St. Louis University

Sungkyunkwan University

Sun Yat-Sen University

Swiss Group for Clinical Cancer Research

Sydney Cancer Centre

Symbion Research International

Syndax Pharmaceuticals

Syneos Health

Takara Bio Inc.

Technical University of Dresden

Tel Aviv University

Temple University

Tesaro

Thallion Pharmaceuticals

The Christie NHS Foundation Trust

The Cleveland Clinic

The First People's Hospital of Changzhou

The Jewish General Hospital, Montreal QC, Canada

The Norwegian Melanoma Group

The Parker Institute

Theradex

The University of Texas, Dallas

The University of Texas Health Science Center, Houston

Threshold Pharmaceuticals

Titan Pharmaceuticals

TransMolecular

TriHealth

Ultimovacs AS

Union Therapeutics

Universidad Complutense de Madrid

Universitaetsklinikum Schleswig-Holstein

Universitair Ziekenhuis Brussel

University Hospital, Essen

University of Alabama

University of Basel

University of Bergen

University of Bern

University of Caen-Normandie

University of Calgary

University of California, Davis

University of California, Irvine

University of California, San Diego

University of California, San Francisco

University of Cambridge

University of Chicago

University of Colorado, Denver

University of Connecticut

University of Edinburgh

University of Florida

University of Geneva

University of Genoa

University of Groningen

University of Heidelberg

University of Iowa

University of Leeds

University of Lille

University of Liverpool

University of Louisville

University of Maryland

University of Maryland, Baltimore County

University of Medicine and Dentistry of New Jersey

University of Miami

University of Michigan

University of Minnesota

University of Montpellier

University of Montreal

University of New Mexico

University of Nice Sophia Antipolis

University of North Carolina at Chapel Hill

University of Nottingham

University of Paris

University of Regensburg

University of Rochester

University of Southern California

University of Strasbourg

University of Sydney

University of Texas, San Antonio

University of Toronto

University of Toulouse

University of Turku

University of Utah

University of Valencia

University of Vienna

University of Western Australia

University of Western Ontario

University of Wisconsin

University of Zurich

Uppsala University

Vanderbilt University

Vanquish Oncology, Inc.

Vastra Gotaland Region

Vedanta Biosciences, Inc.

Verastem, Inc.

Viralytics

Vita-Salute University of Milano. Italy

Vyriad, Inc.

Washington University in St. Louis

Wuhan Binhui Biotechnology Co., Ltd.

Xcovery

Yale University

Yeshiva University

Yonsei University

Yorkshire Cancer Research

Ziopharm

Organization Involved with Phase 1 Indications (121)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.